Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2016 16:05 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Announces Closing of Public Offerings and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the closing of its previously announced underwritten offerings of (i)...
October 19, 2016 09:01 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Announces Pricing of $25 Million Offering of Securities

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of underwritten offerings of (i) 4,935,500 shares of its...
October 18, 2016 16:01 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it intends to offer and sell, subject to market and other...
October 18, 2016 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals to Present at the Dawson James Securities 2nd Annual Small Cap Growth Stock Conference

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Chief Financial Officer of Sunesis, will present at...
October 13, 2016 16:05 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing Authorization Application for Vosaroxin

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has submitted its responses to European Medicines Agency (EMA)...
September 12, 2016 06:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Presents Dose Escalation Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK inhibitor SNS-062

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced results from the Company’s Phase 1A study in healthy volunteers...
September 07, 2016 14:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Announces 1-for-6 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated...
September 01, 2016 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Pharmaceuticals Announces Poster Presentation on Preliminary Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 at the European School of Haematology’s 2nd International Conference on New Concepts in B-Cell Malignancies

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that a poster detailing preliminary results from the Company’s Phase 1A...
August 31, 2016 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences: ...
August 25, 2016 07:00 ET | Source: Sunesis Pharmaceuticals Inc

Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of an article detailing the molecular and pharmacologic...